LENZ Therapeutics financials
$3.86−2.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $1.9M | $1.6M | $12.5M | $5.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $5.2M | $825.0K | $1.2M | $12.5M | $5.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 94.9% | 43.4% | 73.7% | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$34.2M | -$44.1M | -$38.5M | -$18.9M | -$16.9M | -$16.9M | -$15.2M | -$12.9M | -$14.4M | -$16.1M |
| Net income | -$31.9M | -$41.5M | -$35.9M | -$16.7M | -$14.9M | -$14.6M | -$12.5M | -$10.2M | -$10.3M | -$16.6M |
| Net margin | −581.8% | −2182.4% | −2257.6% | −133.6% | −298.2% | — | — | — | — | — |
| Diluted EPS | $-1.02 | $-1.32 | $-1.15 | $-0.59 | $-0.53 | $-0.53 | $-0.45 | $-0.38 | $-0.40 | $-3.53 |
| EBITDA | -$34.1M | -$44.0M | -$38.4M | -$18.8M | -$16.8M | -$16.9M | -$15.2M | -$12.9M | -$14.3M | -$16.1M |
| Operating cash flow | -$38.7M | -$33.6M | -$33.0M | -$8.6M | -$11.5M | -$16.0M | -$9.1M | -$10.6M | -$15.8M | -$23.9M |
| Free cash flow | -$38.7M | -$33.6M | -$33.1M | -$9.0M | -$11.7M | -$16.2M | -$9.2M | -$10.8M | -$15.9M | -$23.9M |
| Diluted shares | 31.4M | 31.4M | 31.1M | 28.5M | 28.1M | 27.5M | 27.6M | 27.2M | 25.6M | 4.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.2M | $24.8M | $25.2M | $25.4M | $37.6M | $23.0M |
| Short-term investments | $195.8M | $233.6M | $267.2M | $176.8M | $171.9M | $170.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $236.6M | $272.5M | $305.9M | $210.7M | $217.3M | $201.3M |
| Total liabilities | $17.3M | $26.0M | $21.5M | $16.8M | $11.0M | $9.2M |
| Shareholders' equity | $219.3M | $246.5M | $284.3M | $193.9M | $206.4M | $192.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology